- Home
- HSII vs GERN Comparison
HSII vs GERN Comparison
Compare HSII & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- GERN
- Stock Information
- Founded
- HSII 1953
- GERN 1990
- Country
- HSII United States
- GERN United States
- Employees
- HSII N/A
- GERN N/A
- Industry
- HSII Diversified Commercial Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- GERN Health Care
- Exchange
- HSII Nasdaq
- GERN Nasdaq
- Market Cap
- HSII 1.1B
- GERN 893.2M
- IPO Year
- HSII 1999
- GERN 1996
- Fundamental
- Price
- HSII $50.37
- GERN $1.40
- Analyst Decision
- HSII Buy
- GERN Buy
- Analyst Count
- HSII 2
- GERN 8
- Target Price
- HSII $51.00
- GERN $3.71
- AVG Volume (30 Days)
- HSII 95.7K
- GERN 8.0M
- Earning Date
- HSII 11-03-2025
- GERN 08-06-2025
- Dividend Yield
- HSII 1.19%
- GERN N/A
- EPS Growth
- HSII N/A
- GERN N/A
- EPS
- HSII 1.60
- GERN N/A
- Revenue
- HSII $1,155,576,000.00
- GERN $164,447,000.00
- Revenue This Year
- HSII $11.33
- GERN $175.15
- Revenue Next Year
- HSII $0.90
- GERN $56.61
- P/E Ratio
- HSII $31.49
- GERN N/A
- Revenue Growth
- HSII 9.00
- GERN 11877.20
- 52 Week Low
- HSII $35.54
- GERN $1.09
- 52 Week High
- HSII $52.18
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- HSII 60.32
- GERN 51.31
- Support Level
- HSII $49.36
- GERN $1.40
- Resistance Level
- HSII $50.93
- GERN $1.52
- Average True Range (ATR)
- HSII 1.26
- GERN 0.07
- MACD
- HSII -0.03
- GERN -0.01
- Stochastic Oscillator
- HSII 58.49
- GERN 21.05
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.